510729-40-5

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[5-[[(phenylmethoxy)carbonyl]amino]-2-pyridinyl]-, 1,1-dimethylethyl ester
• CAS NO: 510729-40-5
• Molecular Formula: C22H28N4O4
• Molecular Weight: 412.489
• Mol File: 510729-40-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[5-[[(phenylmethoxy)carbonyl]amino]-2-pyridinyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[5-[[(phenylmethoxy)carbonyl]amino]-2-pyridinyl]-, 1,1-dimethylethyl ester(510729-40-5)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[5-[[(phenylmethoxy)carbonyl]amino]-2-pyridinyl]-, 1,1-dimethylethyl ester(510729-40-5)

Safety Data

• Hazardous Substances Data: 510729-40-5(Hazardous Substances Data)

Usage

Chemical structure

1-Piperazinecarboxylic acid, 4-[5-[[(phenylmethoxy)carbonyl]amino]-2-pyridinyl]-, 1,1-dimethylethyl ester

Function

Antihistamine and mast cell stabilizer

Purpose

Relief of symptoms of allergic rhinitis and chronic idiopathic urticaria

Mechanism of action

Blocks the action of histamine, a substance in the body that causes allergy symptoms

Forms available

Oral tablet and ophthalmic solution

Treatment for symptoms

Itchy and watery eyes, runny nose, sneezing

Tolerability

Generally well-tolerated

Safety and effectiveness

Considered a safe and effective treatment for allergies.

Upstream product

• 501-53-1 benzyl chloroformate 
• 119285-07-3 4-(5-aminopyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 4548-45-2 2-chloro-5-nitropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 193902-78-2 tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate 

Relevant articles and documents

Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives

In this study, a series of 3-(3-pyridyl)-oxazolidone-5-methyl ester derivatives was synthesized and characterized by1H NMR,13C NMR, and LC-MS. The conducted screening antibacterial studies of the new 3-(3-pyridyl)-oxazolidone-5-methyl ester derivatives established that the methyl sulfonic acid esters have broad activity spectrum towards Staphylococcus aureus, Streptococcus pneu-moniae, Bacillus subtilis and Staphylococcus epidermidis. Among them, compound 12e has the most potent activity, with an MIC of 16 μg/mL against B.subtilis, and could reduce the instantaneous growth rate of bacteria. Furthermore, molecular docking studies were also simulated for compound 12e to predict the specific binding mode of this compound. In addition, anthelmintic activity of these compounds was also evaluated against adult Indian earthworms (Pheretima posthuman). The results showed that compound 11b had the best effect. These results above can provide experimental ref-erence for the development of novel antibacterial and anthelmintic drugs.

NEW COMPOUNDS AS ANTIBACTERIAL AGENTS

The present invention provides novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel oxazolidinone derivatives of the general formula (I).

Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids

Oxazolidinone-quinolone hybrids that combine the pharmacophores of a quinolone and an oxazolidinone were synthesised and shown to be active against a variety of resistant and susceptible Gram-positive and fastidious Gram-negative organisms. The best compo